https://stock.noler.com/us/stock/calypte-biomedical-corp https://stock.noler.com/us/stock/calypte-biomedical-corp/accounts-payable-and-accrued-liabilities-current https://stock.noler.com/us/stock/calypte-biomedical-corp/accounts-payable-trade-current https://stock.noler.com/us/stock/calypte-biomedical-corp/accounts-receivable https://stock.noler.com/us/stock/calypte-biomedical-corp/accrued-income-taxes-current https://stock.noler.com/us/stock/calypte-biomedical-corp/accrued-professional-fees-current https://stock.noler.com/us/stock/calypte-biomedical-corp/accrued-royalties-current https://stock.noler.com/us/stock/calypte-biomedical-corp/accumulated-depreciation https://stock.noler.com/us/stock/calypte-biomedical-corp/activist-13d-13g-form-sc-13d https://stock.noler.com/us/stock/calypte-biomedical-corp/activist-13d-13g-form-sc-13g https://stock.noler.com/us/stock/calypte-biomedical-corp/additional-paid-in-capital https://stock.noler.com/us/stock/calypte-biomedical-corp/allocated-share-based-compensation-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/amended-reports-10-k https://stock.noler.com/us/stock/calypte-biomedical-corp/amended-reports-10-q https://stock.noler.com/us/stock/calypte-biomedical-corp/antidilutive-securities-excluded-from-computation-of-earnings-per-share-amount https://stock.noler.com/us/stock/calypte-biomedical-corp/aoci https://stock.noler.com/us/stock/calypte-biomedical-corp/auction-market-preferred-securities-stock-series-liquidation-value https://stock.noler.com/us/stock/calypte-biomedical-corp/capital-expenditures https://stock.noler.com/us/stock/calypte-biomedical-corp/cash-and-equivalents https://stock.noler.com/us/stock/calypte-biomedical-corp/cash-flow-breakdown https://stock.noler.com/us/stock/calypte-biomedical-corp/common-stock-capital-shares-reserved-for-future-issuance https://stock.noler.com/us/stock/calypte-biomedical-corp/common-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/calypte-biomedical-corp/common-stock-value https://stock.noler.com/us/stock/calypte-biomedical-corp/concentration-risk-percentage https://stock.noler.com/us/stock/calypte-biomedical-corp/conversion-of-stock-amount-converted https://stock.noler.com/us/stock/calypte-biomedical-corp/convertible-debt-current https://stock.noler.com/us/stock/calypte-biomedical-corp/cost-of-goods-sold https://stock.noler.com/us/stock/calypte-biomedical-corp/cover-page-shares-outstanding https://stock.noler.com/us/stock/calypte-biomedical-corp/current-assets https://stock.noler.com/us/stock/calypte-biomedical-corp/current-liabilities https://stock.noler.com/us/stock/calypte-biomedical-corp/debt-conversion-converted-instrument-amount https://stock.noler.com/us/stock/calypte-biomedical-corp/debt-conversion-converted-instrument-shares-issued https://stock.noler.com/us/stock/calypte-biomedical-corp/debt-conversion-original-debt-amount https://stock.noler.com/us/stock/calypte-biomedical-corp/deferred-revenue https://stock.noler.com/us/stock/calypte-biomedical-corp/deferred-tax-assets-gross https://stock.noler.com/us/stock/calypte-biomedical-corp/deferred-tax-assets-net https://stock.noler.com/us/stock/calypte-biomedical-corp/deferred-tax-assets-operating-loss-carryforwards https://stock.noler.com/us/stock/calypte-biomedical-corp/deferred-tax-assets-other https://stock.noler.com/us/stock/calypte-biomedical-corp/deferred-tax-assets-tax-credit-carryforwards-research https://stock.noler.com/us/stock/calypte-biomedical-corp/deferred-tax-assets-valuation-allowance https://stock.noler.com/us/stock/calypte-biomedical-corp/depreciation-and-amortization https://stock.noler.com/us/stock/calypte-biomedical-corp/diluted-shares https://stock.noler.com/us/stock/calypte-biomedical-corp/earnings-per-share-basic-and-diluted https://stock.noler.com/us/stock/calypte-biomedical-corp/employee-related-liabilities-current https://stock.noler.com/us/stock/calypte-biomedical-corp/equity-method-investment-ownership-percentage https://stock.noler.com/us/stock/calypte-biomedical-corp/exchange-rate-effect-on-cash https://stock.noler.com/us/stock/calypte-biomedical-corp/extinguishment-of-debt-amount https://stock.noler.com/us/stock/calypte-biomedical-corp/financing-cash-flow https://stock.noler.com/us/stock/calypte-biomedical-corp/finite-lived-intangible-assets-accumulated-amortization https://stock.noler.com/us/stock/calypte-biomedical-corp/finite-lived-intangible-assets-net https://stock.noler.com/us/stock/calypte-biomedical-corp/foreign-pretax-income https://stock.noler.com/us/stock/calypte-biomedical-corp/gain-loss-on-disposition-of-assets https://stock.noler.com/us/stock/calypte-biomedical-corp/gain-loss-on-sale-of-property-plant-equipment https://stock.noler.com/us/stock/calypte-biomedical-corp/gains-losses-on-restructuring-of-debt https://stock.noler.com/us/stock/calypte-biomedical-corp/income-loss-before-extraordinary-items-and-cumulative-effect-of-change-in-accounting-principle https://stock.noler.com/us/stock/calypte-biomedical-corp/income-loss-from https://stock.noler.com/us/stock/calypte-biomedical-corp/income-loss-from-discontinued-operations-net-of-tax-attributable-to-noncontrolling-interest https://stock.noler.com/us/stock/calypte-biomedical-corp/income-loss-from-discontinued-operations-net-of-tax-attributable-to-reporting-entity https://stock.noler.com/us/stock/calypte-biomedical-corp/income-loss-from-discontinued-operations-net-of-tax-per-basic-share https://stock.noler.com/us/stock/calypte-biomedical-corp/income-loss-from-per-basic-share https://stock.noler.com/us/stock/calypte-biomedical-corp/income-tax https://stock.noler.com/us/stock/calypte-biomedical-corp/income-tax-at-federal-statutory-rate https://stock.noler.com/us/stock/calypte-biomedical-corp/increase-decrease-in-accounts-payable-and-accrued-liabilities https://stock.noler.com/us/stock/calypte-biomedical-corp/increase-decrease-in-inventories https://stock.noler.com/us/stock/calypte-biomedical-corp/increase-decrease-in-prepaid-deferred-expense-and-other-assets https://stock.noler.com/us/stock/calypte-biomedical-corp/increase-decrease-in-receivables https://stock.noler.com/us/stock/calypte-biomedical-corp/insider-transactions-corporate-securities https://stock.noler.com/us/stock/calypte-biomedical-corp/insider-transactions-stock-options https://stock.noler.com/us/stock/calypte-biomedical-corp/insider-transactions-warrants https://stock.noler.com/us/stock/calypte-biomedical-corp/insider-transactions-warrants/purchases https://stock.noler.com/us/stock/calypte-biomedical-corp/interest-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/interest-expense-on-debt https://stock.noler.com/us/stock/calypte-biomedical-corp/interest-expense-other https://stock.noler.com/us/stock/calypte-biomedical-corp/interest-expense-other-long-term-debt https://stock.noler.com/us/stock/calypte-biomedical-corp/interest-paid https://stock.noler.com/us/stock/calypte-biomedical-corp/interest-payable-current https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory-finished-goods https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory-finished-goods-net-of-reserves https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory-raw-materials https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory-raw-materials-net-of-reserves https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory-valuation-reserves https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory-work-in-process https://stock.noler.com/us/stock/calypte-biomedical-corp/inventory-work-in-process-net-of-reserves https://stock.noler.com/us/stock/calypte-biomedical-corp/investing-cash-flow https://stock.noler.com/us/stock/calypte-biomedical-corp/late-filing-notices-nt-10-k https://stock.noler.com/us/stock/calypte-biomedical-corp/late-filing-notices-nt-10-q https://stock.noler.com/us/stock/calypte-biomedical-corp/lease-and-rental-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/net-change-in-cash https://stock.noler.com/us/stock/calypte-biomedical-corp/net-income https://stock.noler.com/us/stock/calypte-biomedical-corp/notes-payable-current https://stock.noler.com/us/stock/calypte-biomedical-corp/oci-foreign-currency-transaction-and-translation-adjustment-net-of-tax-change https://stock.noler.com/us/stock/calypte-biomedical-corp/operating-cash-flow https://stock.noler.com/us/stock/calypte-biomedical-corp/operating-expenses https://stock.noler.com/us/stock/calypte-biomedical-corp/operating-income https://stock.noler.com/us/stock/calypte-biomedical-corp/operating-lease-payments-due-current https://stock.noler.com/us/stock/calypte-biomedical-corp/operating-lease-payments-due-in-two-years https://stock.noler.com/us/stock/calypte-biomedical-corp/other-accrued-liabilities-current https://stock.noler.com/us/stock/calypte-biomedical-corp/other-income https://stock.noler.com/us/stock/calypte-biomedical-corp/other-noncash-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/other-noncash-income https://stock.noler.com/us/stock/calypte-biomedical-corp/other-noncurrent-assets https://stock.noler.com/us/stock/calypte-biomedical-corp/paid-in-capital-stock-compensation https://stock.noler.com/us/stock/calypte-biomedical-corp/paid-in-kind-interest https://stock.noler.com/us/stock/calypte-biomedical-corp/payments-to-acquire-machinery-and-equipment https://stock.noler.com/us/stock/calypte-biomedical-corp/preferred-shares-facts https://stock.noler.com/us/stock/calypte-biomedical-corp/preferred-stock-par-or-stated-value-per-share https://stock.noler.com/us/stock/calypte-biomedical-corp/preferred-stock-shares-authorized https://stock.noler.com/us/stock/calypte-biomedical-corp/preferred-stock-shares-issued https://stock.noler.com/us/stock/calypte-biomedical-corp/preferred-stock-shares-outstanding https://stock.noler.com/us/stock/calypte-biomedical-corp/preferred-stock-value https://stock.noler.com/us/stock/calypte-biomedical-corp/prepaid-expense-current https://stock.noler.com/us/stock/calypte-biomedical-corp/pretax-income-domestic https://stock.noler.com/us/stock/calypte-biomedical-corp/pretax-income-minority-interest-and-income-loss-from-equity-method-investments https://stock.noler.com/us/stock/calypte-biomedical-corp/proceeds-from-contributed-capital https://stock.noler.com/us/stock/calypte-biomedical-corp/proceeds-from-sale-of-other-investments https://stock.noler.com/us/stock/calypte-biomedical-corp/property-plant-and-equipment-gross https://stock.noler.com/us/stock/calypte-biomedical-corp/property-plant-equipment https://stock.noler.com/us/stock/calypte-biomedical-corp/public-float https://stock.noler.com/us/stock/calypte-biomedical-corp/repayments-of-notes-payable https://stock.noler.com/us/stock/calypte-biomedical-corp/research-and-development https://stock.noler.com/us/stock/calypte-biomedical-corp/retained-earnings https://stock.noler.com/us/stock/calypte-biomedical-corp/sale-of-stock-price-per-share https://stock.noler.com/us/stock/calypte-biomedical-corp/sales-revenue-goods-net https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-comment-letters-corresp https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-comment-letters-upload https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-10-k https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-10-k405 https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-10-q https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-10ksb https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-10qsb https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-25 https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-8-a12b https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-8-a12g https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-8-k https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-certamx https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-ct-order https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-def-14a https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-defa14a https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-defr14a https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-ntn-10k https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-pre-14a https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-prer14a https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-pres14a https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-regdex https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-revoked https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-s-2 https://stock.noler.com/us/stock/calypte-biomedical-corp/sec-filings-sb-2 https://stock.noler.com/us/stock/calypte-biomedical-corp/secondary-offerings-form-424b3 https://stock.noler.com/us/stock/calypte-biomedical-corp/secondary-offerings-form-effect https://stock.noler.com/us/stock/calypte-biomedical-corp/secondary-offerings-form-pos-am https://stock.noler.com/us/stock/calypte-biomedical-corp/secondary-offerings-form-rw https://stock.noler.com/us/stock/calypte-biomedical-corp/secondary-offerings-form-s-1 https://stock.noler.com/us/stock/calypte-biomedical-corp/secondary-offerings-form-s-3 https://stock.noler.com/us/stock/calypte-biomedical-corp/secondary-offerings-form-s-8 https://stock.noler.com/us/stock/calypte-biomedical-corp/sga-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/share-price https://stock.noler.com/us/stock/calypte-biomedical-corp/shareholders-equity https://stock.noler.com/us/stock/calypte-biomedical-corp/shares-authorized https://stock.noler.com/us/stock/calypte-biomedical-corp/shares-issued https://stock.noler.com/us/stock/calypte-biomedical-corp/shares-issued-shares-new-issues https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-award-fair-value-assumptions-expected-dividend-rate https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-award-fair-value-assumptions-expected-volatility-rate https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-award-options-exercises-in-period-average-exercise-price https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-award-options-expirations-in-period-average-exercise-price https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-award-options-forfeitures-in-period-average-exercise-price https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-award-options-grants-in-period-average-exercise-price https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-based-compensation https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-compensation-tax-benefit-from-compensation-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-issued-new-shares-sold https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-issued-shares-issued-for-options-exercised https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-exercisable-average-exercise-price https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-exercisable-intrinsic-value https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-exercisable-number https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-expirations-in-period https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-forfeitures-in-period https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-grants-in-period-gross https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-outstanding-average-exercise-price https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-outstanding-intrinsic-value https://stock.noler.com/us/stock/calypte-biomedical-corp/stock-options-outstanding-number https://stock.noler.com/us/stock/calypte-biomedical-corp/tax-rate-reconciliation-at-federal-statutory-income-tax-rate https://stock.noler.com/us/stock/calypte-biomedical-corp/tax-reconciliation-nondeductible-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/tax-reconciliation-other-adjustments https://stock.noler.com/us/stock/calypte-biomedical-corp/tax-reconciliation-state-and-local-income-taxes https://stock.noler.com/us/stock/calypte-biomedical-corp/temporary-equity-carrying-amount https://stock.noler.com/us/stock/calypte-biomedical-corp/temporary-equity-carrying-amount-attributable-to-parent https://stock.noler.com/us/stock/calypte-biomedical-corp/temporary-equity-par-or-stated-value-per-share https://stock.noler.com/us/stock/calypte-biomedical-corp/temporary-equity-shares-authorized https://stock.noler.com/us/stock/calypte-biomedical-corp/temporary-equity-shares-issued https://stock.noler.com/us/stock/calypte-biomedical-corp/temporary-equity-shares-outstanding https://stock.noler.com/us/stock/calypte-biomedical-corp/total-assets https://stock.noler.com/us/stock/calypte-biomedical-corp/total-liabilities https://stock.noler.com/us/stock/calypte-biomedical-corp/total-liabilities-and-equity https://stock.noler.com/us/stock/calypte-biomedical-corp/utb-income-tax-penalties-and-interest-accrued https://stock.noler.com/us/stock/calypte-biomedical-corp/utb-income-tax-penalties-and-interest-expense https://stock.noler.com/us/stock/calypte-biomedical-corp/valuation-allowance-deferred-tax-asset-change-in-amount https://stock.noler.com/us/stock/calypte-biomedical-corp/weighted-average-number-of-share-outstanding-basic-and-diluted